Literature DB >> 11120933

Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis.

J E Leigh1, M Barousse, R K Swoboda, T Myers, S Hager, N A Wolf, J L Cutright, J Thompson, J D Sobel, P L Fidel .   

Abstract

Oropharyngeal candidiasis (OPC), as opposed to vulvovaginal candidiasis (VVC), is a common opportunistic infection in human immunodeficiency virus (HIV)-positive persons that correlates with reduced CD4 T cell counts. Although cell-mediated immunity (CMI) by CD4 Th1-type cells is considered to be the predominant host defense against mucosal candidiasis, the immune factors associated with susceptibility to OPC in HIV-positive persons are not well understood. This study investigated Candida-specific systemic CMI in HIV-positive persons with OPC and/or VVC. Reductions in delayed skin test reactivity to Candida antigen were observed in HIV-positive persons with CD4 cell counts <200 cells/microL, irrespective of the presence of mucosal infection. Likewise, despite the correlate of OPC with reduced CD4 cell counts in HIV-positive persons, differences in Candida-specific peripheral blood mononuclear cell proliferation and Th1/Th2 cytokine production between HIV-positive and HIV-negative persons were not consistent in a manner to suggest that deficiencies in Candida-specific systemic CMI account solely for the susceptibility to OPC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120933     DOI: 10.1086/317944

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis.

Authors:  K Quimby; E A Lilly; M Zacharek; K McNulty; J E Leigh; J E Vazquez; P L Fidel
Journal:  Oral Dis       Date:  2011-09-30       Impact factor: 3.511

Review 2.  Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis.

Authors:  P L Fidel
Journal:  Adv Dent Res       Date:  2011-04

Review 3.  Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.

Authors:  Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  Cytokine       Date:  2011-12-17       Impact factor: 3.861

4.  Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART.

Authors:  Kate Burgess; Patricia Price; Ian R James; Shelley F Stone; Niamh M Keane; Andrew Y F Lim; John R Warmington; Martyn A French
Journal:  J Clin Immunol       Date:  2006-03-28       Impact factor: 8.317

5.  Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells.

Authors:  C Steele; J Leigh; R Swoboda; H Ozenci; P L Fidel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans.

Authors:  Chad Steele; Paul L Fidel
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

7.  Vaginal and oral epithelial cell anti-Candida activity.

Authors:  Fatema Nomanbhoy; Chad Steele; Junko Yano; Paul L Fidel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Characterization of CD8+ T cells and microenvironment in oral lesions of human immunodeficiency virus-infected persons with oropharyngeal candidiasis.

Authors:  Kelly M McNulty; Jananya Plianrungsi; Janet E Leigh; Donald Mercante; Paul L Fidel
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.

Authors:  Paul L Fidel; Melissa Barousse; Terri Espinosa; Mercedes Ficarra; Joy Sturtevant; David H Martin; Alison J Quayle; Kathleen Dunlap
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.